The Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute sponsors clinical trials of investigational agents within its Phase I and and Phase II clinical trials networks, as well as through the large Cooperative Groups. The CTEP Investigational Drug Branch welcomes hematology and oncology fellows and junior faculty to spend a 1-month rotation to observe and to participate in our day-to-day operations, including Letter of Intent (LOI) and protocol reviews, meetings with pharmaceutical and biotechnology companies regarding the development of new agents and biomarkers, and in discussions with the FDA . Visiting physicians have the opportunity to participate in concept reviews, in which prioritization of Cooperative Group Phase III clinical trials are determined. Former visiting fellows and junior faculty have found the experience gained during their rotation to be invaluable for their academic career development by providing them with important insights for the preparation of successful LOIs and the conduct of clinical trials. This experience has also been useful for those choosing to pursue a pharmaceutical or a regulatory career path.
Those who are interested in learning more about the elective rotation may contact Dr. Igor Espinoza-Delgado, EspinozaIg@mail.nih.gov, 301-496-1196.